Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer

Published on 19 May 2023 on Benzinga via Yahoo Finance

Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer

Candel Therapeutics Inc (NASDAQ: CADL) announced new data from an ongoing phase 1 trial of its herpes simplex virus-1 (HSV-1) replication-competent viral immunotherapy candidate, CAN-3110, in patients with high-grade glioma that has recurred after standard of care (SoC) treatment.

Read the rest of the article

NASDAQ.CADL price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag

Candel Therapeutics, Inc. CADL announced that the FDA has granted orphan drug designation to its ...

Zacks via Yahoo Finance 12 Apr 2024

Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too...

Key Insights The considerable ownership by retail investors in Candel Therapeutics indicates that...

Simply Wall St. via Yahoo Finance 6 Apr 2024

Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study

Candel Therapeutics, Inc.’s CADL shares skyrocketed 280.9% on Apr 5, after the company announced ...

Zacks via Yahoo Finance 5 Apr 2024

Candel Therapeutics stock jumps as pancreatic cancer treatment shows promise

climbed 15% early Friday after the company released new data from a trial of its experimental can...

Market Watch 5 Apr 2024

After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study

Thursday, Candel Therapeutics Inc (NASDAQ:CADL) released updated interim survival data from the o...

Benzinga via Yahoo Finance 5 Apr 2024

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.35% By Investing.com

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.35%

Investing.com 4 Apr 2024

Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409

Candel Therapeutics, Inc. CADL announced that the FDA has granted Fast Track designation to its i...

Zacks via Yahoo Finance 13 Dec 2023

Pleasing Signs As A Number Of Insiders Buy Candel Therapeutics Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insid...

Simply Wall St. via Yahoo Finance 29 Oct 2023

Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer

Candel Therapeutics Inc (NASDAQ: CADL) announced new data from an ongoing phase 1 trial of its he...

Benzinga via Yahoo Finance 19 May 2023

The Independent Director of Candel Therapeutics, Inc. (NASDAQ:CADL), Joseph Papa, Just Bought A Few...

Even if it's not a huge purchase, we think it was good to see that Joseph Papa, the Independent D...

Simply Wall St. via Yahoo Finance 13 Dec 2022